Julie Gralow, MD, on the implications of the PERSEPHONE trial in early HER2+ breast cancer
Julie Gralow, MD, reflects on the PERSEPHONE trial from the 2018 ASCO Annual MeetingПодробнее
PERSEPHONE: 6 vs. 12-month adjuvant trastuzumab in early breast cancerПодробнее
The PERSEPHONE trial: 6 months and 12 months of trastuzumab in breast cancerПодробнее
Dr. Julie Gralow Discusses T-DM1-Induced ThrombocytopeniaПодробнее
Neelima Denduluri, MD, offers opinion on the PERSEPHONE trial in early HER2+ breast cancerПодробнее
Julie Gralow, MD, regarding the reduction in cardiac events in the PERSEPHONE studyПодробнее
Dr. Julie Gralow Discusses the Antibody Drug Conjugate T-DM1 for Breast CancerПодробнее
Dr. Gralow on the Use of Bisphosphonates in Early-Stage Breast CancerПодробнее
Dr. Gralow Discusses Toxicities Experienced in the SWOG S0307 TrialПодробнее
Dr. Gralow Gives an Analysis of the APT TrialПодробнее
Dr. Julie R. Gralow Discusses Findings from the RxPONDER Study Released at SABCS 2020Подробнее
Julie Gralow, MD, on the KRISTINE studyПодробнее
Julie R. Gralow, MD: The Atlas Trial. Tamoxifen For Five Years or Ten Years?Подробнее
Dr. Gralow on Adjuvant Bisphosphonates for Breast CancerПодробнее
Julie Gralow, MD, summarizes the RxPONDER trial from the 2020 San Antonio Breast Cancer SymposiumПодробнее
Dr. Murthy on Caveats of the PERSEPHONE Trial in Breast CancerПодробнее
Dr. Gralow on Future Research Into Bisphosphonates in Breast CancerПодробнее
Dr. Shafaee on the PERSEPHONE Trial in Early-Stage HER2+ Breast CancerПодробнее
Julie Gralow, MD, comments on the practice-changing implications of the TAILORx studyПодробнее
